Skip to content
Sign in

ENTA · NASDAQ

Enanta Pharmaceuticals (ENTA) Stock Price & Fundamentals

$369.88−1.28%−$4.80End-of-day price as of Oct 9, 2026

Enanta Pharmaceuticals (ENTA) closed at $369.88 on Oct 9, 2026, down 1.28% from the previous close of $374.68.

Share price, past year

1Y +16.59%

52-week range $311.54 – $374.68. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$369.88
Sep 30, 2026$368.80
Aug 31, 2026$371.76
Jul 31, 2026$364.47
Jun 30, 2026$340.40
May 29, 2026$358.84
Apr 30, 2026$325.52
Mar 31, 2026$312.83
Feb 27, 2026$323.79
Jan 30, 2026$324.77
Dec 31, 2025$334.58
Nov 28, 2025$330.48
Oct 31, 2025$331.27

Key statistics

Market cap
$10.77B
P/E (TTM)
—
EPS (TTM)
−$2.42
Revenue (TTM)
$65.26M
Net income (TTM)
−$63.23M
Shares outstanding
29.1M
Dividend yield
—
52-week range
$311.54 – $374.68

Enanta Pharmaceuticals's market cap is $10.77B, based on a share price of $369.88 and 29.1M shares outstanding as of Jun 30, 2026.

Financials

Enanta Pharmaceuticals reported revenue of $65.32M for fiscal 2025, down 3.42% from fiscal 2024.

Enanta Pharmaceuticals reported a net loss of $81.89M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Enanta Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Sep 30, 2025$65.32M−3.4%−$81.89M−125.4%−$3.84−$32.17M
FY2024ended Sep 30, 2024$67.64M−14.6%−$116.05M−171.6%−$5.48−$96.71M
FY2023ended Sep 30, 2023$79.20M−8.1%−$133.82M−169.0%−$6.38−$112.21M
FY2022ended Sep 30, 2022$86.16M−11.2%−$121.76M−141.3%−$5.91−$86.91M
FY2021ended Sep 30, 2021$97.07M−20.7%−$79.00M−81.4%−$3.92−$70.75M
FY2020ended Sep 30, 2020$122.47M−40.3%−$36.17M−29.5%−$1.81$5.64M
FY2019ended Sep 30, 2019$205.20M−0.7%$46.38M22.6%$2.21$66.00M
FY2018ended Sep 30, 2018$206.63M+101.0%$71.96M34.8%$3.48$26.24M
FY2017ended Sep 30, 2017$102.81M+16.5%$17.71M17.2%$0.91$50.15M
FY2016ended Sep 30, 2016$88.27M—$21.67M24.6%$1.13$31.07M
Enanta Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q3 FY2026ended Jun 30, 2026$14.36M−$19.50M−$0.67
Q2 FY2026ended Mar 31, 2026$17.16M−$13.09M−$0.45
Q1 FY2026ended Dec 31, 2025$18.62M−$11.94M−$0.42
Q4 FY2025ended Sep 30, 2025$15.13M−$18.70M−$0.88
Q3 FY2025ended Jun 30, 2025$18.31M−$18.26M−$0.85
Q2 FY2025ended Mar 31, 2025$14.93M−$22.64M−$1.06
Q1 FY2025ended Dec 31, 2024$16.96M−$22.29M−$1.05
Q4 FY2024ended Sep 30, 2024$14.61M−$28.82M−$1.36

Company profile

Name
Enanta Pharmaceuticals, Inc.
Ticker
ENTA
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
4 Kingsbury Avenue, Watertown, MA 02472
Fiscal year ends
September
SEC CIK
0001177648

Recent SEC filings

Frequently asked questions

What is Enanta Pharmaceuticals's stock price?

Enanta Pharmaceuticals (ENTA) closed at $369.88 on Oct 9, 2026, down 1.28% from the previous close of $374.68.

What is Enanta Pharmaceuticals's market cap?

Enanta Pharmaceuticals's market cap is $10.77B, based on a share price of $369.88 and 29.1M shares outstanding as of Jun 30, 2026.

How much revenue does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals reported revenue of $65.32M for fiscal 2025, down 3.42% from fiscal 2024.

Does Enanta Pharmaceuticals pay a dividend?

Enanta Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Enanta Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures